Cephalon announces positive results from research of NUVIGIL in bipolar depression Cephalon, Inc http://propeciasverige.com . Offers announced excellent results from a phase two medical trial of NUVIGIL Tablets [C-IV] simply because adjunctive therapy for treating main depressive disorder in adults with bipolar I disorder. An estimated two million American adults are influenced by bipolar I disorder, which is usually characterized by fluctuations between intense highs and lows in mood. People who have bipolar disorders routine between periods of manic or depressive mood and typically spend more time in the depressed stage of the illness. The eight-week, double-blind, placebo-controlled study evaluated the efficacy and security of NUVIGIL as an adjunctive therapy to feeling stabilizers in 257 individuals with bipolar I disorder, who experienced a major depressive episode that had not been completely managed by their various other treatments.